References
1. Zoppini G., Fedeli U., Schievano E., Dauriz M., Targher G., Bonora E., et al. Mortality from infectious diseases in diabetes. Nutr Metab Cardiovasc Dis. 2018; 28: 444–50.
2. Al-Baadani A.M., Elzein F.E., Alhemyadi S.A., Khan O.A., Albenmousa A.H., Idrees M.M. Characteristics and outcome of viral pneumonia caused by influenza and Middle East respiratory syndrome-coronavirus infections: a 4-year experience from a tertiary care center. Ann Thorac Med. 2019; 14 (8): 179–85.
3. Bornstein S.R., Rubino F., Khunti K., Mingrone G., Hopkins D., Birkenfeld A.L., et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 2020; 8 (6): 546–50.
4. Lihua Zhu, Zhi-Gang She, Xu Cheng, Jiao Guo, Bing-Hong Zhang, Hongliang Li. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020; 31 (6): 1068–77.
5. Fadini G.P., Morieri M.L., Longato E., Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. 2020; 127 (43): 867–9.
6. Roncon L., Zuin M., Rigatelli G., Zuliani G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Virol. 2020; 127: 104354.
7. World Health Organization. COVID-19 Weekly Epidemiological Update. Edition 87, published 12 April 2022. Geneva: WHO, 2022.
8. Pawelec G. Age and immunity: what is «immunosenescence»? Exp Gerontol. 2018; 105: 4–9.
9. Fung S.Y., Yuen K.S., Ye Z.W., Chan C.P., Jin D.Y. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect. 2020; 9: 558–70.
10. Chen Y., Klein S.L., Garibaldi B.T., Li H., Wu C., Osevala N.M., et al. Aging in COVID-19: vulnerability, immunity and intervention. Ageing Res Rev. 2021; 65: 101205.
11. B.M., de Oliveira M.H.S., Benoit S., et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020; 58 (7): 1021–8.
12. Luo X., Zhou W., Yan X., et al. Prognostic value of C-reactive protein in patients with coronavirus 2019. Clin Infect Dis. 2020; 71 (16): 2174–9.
13. Cosentino F., Moscatt V., Marino A., et al. Clinical characteristics and predictors of death among hospitalized patients infected with SARS-CoV-2 in Sicily, Italy: a retrospective observational study. Biomed Rep. 2022; 16 (5): 34.
14. Cariou B., et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020; 63: 1500–15.
15. Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8 (4): 420–2.
16. Cai Q., Huang D., Yu H., Zhu Z., Xia Z., Su Y., et al. COVID-19: abnormal liver function tests. J Hepatol. 2020; 73 (3): 566–74.
17. Hartl L., Haslinger K., Angerer M., Jachs M., Simbrunner B., Bauer D.J.M., et al. Age-adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID-19 patients. Liver Int. 2022; 42 (6): 1297–307.
18. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395: 507–13.
19. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382: 1708–20.
20. Han Y., Zhang H., Mu S., et al. Lactate dehydrogenase, a risk factor of severe COVID-19 patients: a retrospective and observational study. Aging. 2020; 12 (12): 11 245–58.